Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
Список исп. литературыСкрыть список 1. Вербицкая С.В. Ведение пациентов с постинсультной деменцией. Неврология, нейропсихиатрия, психосоматика. 2013; (спецвып. 2): 46–9. / Verbitskaia S.V. Vedenie patsientov s postinsul'tnoi dementsiei. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2013; (spetsvyp. 2): 46–9. [in Russian] 2. Коваленко Е.А., Боголепова А.Н. Постинсультные когнитивные нарушения: новые перспективы нейропротекции. Фарматека. 2016; 9: 37–42. / Kovalenko E.A., Bogolepova A.N. Postinsul'tnye kognitivnye narusheniia: novye perspektivy neiroprotektsii. Farmateka. 2016; 9: 37–42. [in Russian] 3. Котов С.В., Исакова Е.В., Чатаева Г.С., Прохорова Н.В. Акатинол мемантин в лечении больных ишемическим инсультом. Психиатрия и психофармакотерапия. 2005; 7 (6): 343–5. / Kotov S.V., Isakova E.V., Chataeva G.S., Prokhorova N.V. Akatinol memantin v lechenii bol'nykh ishemicheskim insul'tom. Psychiatry and Psychopharmacotherapy. 2005; 7 (6): 343–5. [in Russian] 4. Левин О.С., Васенина Е.Е. Применение Акатинола Мемантина в клинической практике. Сов. терапия в психиатрии и неврологии. 2015; 1: 24–33. / Levin O.S., Vasenina E.E. Primenenie Akatinola Memantina v klinicheskoi praktike. Sov. terapiia v psikhiatrii i nevrologii. 2015; 1: 24–33. [in Russian] 5. Макотрова Т.А., Трусова Н.А., Шрадер Н.И., Левин О.С. Нейропротективный потенциал акатинола-мемантина при ишемическом инсульте. Журн. неврологии и психиатрии им. C.C.Корсакова. 2013; 113 (7–2): 82–5. / Makotrova T.A., Trusova N.A., Shrader N.I., Levin O.S. Neiroprotektivnyi potentsial akatinola-memantina pri ishemicheskom insul'te. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2013; 113 (7–2): 82–5. [in Russian] 6. Парфенов В.А., Вахнина Н.В., Никитина Л.Ю. Когнитивные нарушения при инсульте и их лечение мемантином. Клин. геронтология. 2005; 11 (8): 49–52. / Parfenov V.A., Vakhnina N.V., Nikitina L.Iu. Kognitivnye narusheniia pri insul'te i ikh lechenie memantinom. Klin. gerontologiia. 2005; 11 (8): 49–52. [in Russian] 7. Скворцова В.И., Стаховская Л.В., Денисова И.А. и др. Эффективность мемантина для лечения больных с дисциркуляторной энцефалопатией. Consilium Medicum. 2007; 9 (2): 82–8. / Skvortsova V.I., Stakhovskaia L.V., Denisova I.A. et al. Effektivnost' memantina dlia lecheniia bol'nykh s distsirkuliatornoi entsefalopatiei. Consilium Medicum. 2007; 9 (2): 82–8. [in Russian] 8. Хатькова С.Е., Акулов М.А., Орлова О.Р., Орлова А.С. Современные подходы к реабилитации больных после инсульта. Нервные болезни. 2016; 3: 27–33. / Khat'kova S.E., Akulov M.A., Orlova O.R., Orlova A.S. Sovremennye podkhody k reabilitatsii bol'nykh posle insul'ta. Nervnye bolezni. 2016; 3: 27–33. [in Russian] 9. Aarts MM, Tymianski M. TRPMs and neuronal cell death. Pflugers Arch 2005; 451: 243–9. 10. Allgaier M, Allgaier C. An update on drug treatment options of Alzheimer's disease. Front Biosci (Landmark Ed) 2014; 19: 1345–54. 11. Babu CS, Ramanathan M. Post-ischemic administration of nimodipine following focal cerebral ischemic-reperfusion injury in rats alleviated excitotoxicity, neurobehavioural alterations and partially the bioenergetics. Int J Dev Neurosci 2011; 29: 93–105. 12. Barbancho MA, Berthier ML, Navas-Sanchez P et al. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study. Brain Lang 2015; 145–6. 13. Belagaje SR. Stroke Rehabilitation. Continuum (Minneap Minn) 2017; 23 (1, Cerebrovascular Disease): 238–53. 14. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984; 43 (5): 1369–74. 15. Beristain X, Golombievski E. Pharmacotherapy to Enhance Cognitive and Motor Recovery Following Stroke. Drugs Aging 2015; 32 (10): 765–72. 16. Berthier ML, Green C, Lara JP et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol 2009; 65 (5): 577–85. 17. Besancon E, Guo S, Lok J, Tymianski M, Lo EH. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol Sci 2008; 29: 268–75. 18. Block F, Schwarz M. Memantine reduce functional and morfological consequences induced by global ischemia in rats. Neurosci Lett 1996; 208 (1): 41–4. 19. Cassidy JM, Cramer SC. Spontaneous and Therapeutic-Induced Mechanisms of Functional Recovery After Stroke. Transl Stroke Res 2017; 8 (1): 33–46. 20. Castillo J, Davalos A, Naveiro J, Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996; 27 (6): 1060–5. 21. Centers for Disease Control and Prevention (CDC) Outpatient rehabilitation among stroke survivors-21 states and the District of Columbia, 2005. MMWR Morb Mortal Wkly Rep 2007; 56: 504–7. 22. Chen B, Wang G, Li W et al. Memantine attenuates cell apoptosis by suppressing the calpain-caspase-3 pathway in an experimental model of ischemic stroke. Exp Cell Res 2017; 6. PII: S0014-4827(16)30450-5. DOI: 10.1016 23. Chen HS, Wang YF, Rayudu PV et al. Neuroprotective concentration of the N-methyl-D-aspartate openchannel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or longterm potentiation. Neuroscience 1998; 86 (4): 1121–32. 24. Chen JC, Hsu-Chou H, Lu JL et al. Down-regulation of the glial glutamate transporter GLT-1 in rat hippocampus and striatum and its modulation by a group III metabotropic glutamate receptor antagonist following transient global forebrain ischemia. Neuropharmacology. 2005; 49 (5): 703–14. 25. Culmsee C, Junker V, Kremers W et al. Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. Stroke 2004; 35 (5): 1197–202. 26. Cummings JL, Schneider E, Tariot P et al. Behavioral effects of memantine in Alzheimer's disease patients receiving donepezil treatment. Neurology 2006; 67: 57–63. 27. Davis SM, Lees KR, Albers GW et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000; 31: 347–54. 28. Dawson LA, Djali S, Gonzales C et al. Characterization of transient focal ischemia-induced increases in extracellular glutamate and aspartate in spontaneously hypertensive rats. Brain Res Bull 2000; 53 (6): 767–76. 29. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391–7. 30. Feigin VL, Lawes CM, Bennett DA et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8: 355–69. 31. Francis PT. Behavioral effects of memantine: understanding the pharmacological rationale. Eur J Neurology 2007; 14 (S. 1): 2098. 32. Frankiwicz T, Parsons CG. Effects of NMDA-receptors antagonists on long-term potentiation and hypoxic: hypoglycaemic excitotoxicity in hyppocampal slices. Soc Neurosci Abs 1998; 12 (24): 179. 33. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioral symptoms in Alzheimer disease patients. Int J Geriatr Psychiatry 2005; 20: 459–64. 34. Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009; 40 (Suppl. 3): S111–S114. 35. Go AS, Mozaffarian D, Roger VL, Benjamin EJ et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127 (1): e6–e245. 36. Gorelick PB, Scuteri A, Black SE et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 2672–713. 37. Hamade YJ, Zammar SG, El Tecle NE et al. Brain plasticity after stroke: the potential role of memantine. Neurosurgery 2014; 75 (4): 18–9. 38. Harris AL, Elder J, Schiff ND et al. Post-stroke apathy and hypersomnia lead to worse outcomes from acute rehabilitation. Transl Stroke Res 2014; 5 (2): 292–300. 39. Hatano S. Variability of the diagnosis of stroke by clinical judgement and by a scoring method. Bull World Health Org 1976; 54: 533–40. 40. Heim C, Sontag KH. Memantine prevent progressive functional neurodegeneration in rats. J Neural Transm Suppl 1995; 46: 117–30. 41. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006; 6: 61–7. 42. Kafi H, Salamzadeh J, Beladimoghadam N et al. Study of the neuroprotective effects of memantine in patients with mild to moderate ischemic stroke. Iran J Pharm Res 2014; 13 (2): 591–8. 43. Kaithoju S. Ischemic Stroke: Risk Stratification, Warfarin Teatment and Outcome Measure. J Atr Fibrillation 2015; 8 (4): 1144. 44. Kilic U, Yilmaz B, Reiter RJ, et al. Effects of memantine and melatonin on signal transduction pathways vascular leakage and brain injury after focal cerebral ischemia in mice. Neuroscience 2013; 237: 268–76. 45. Klegerman ME. Translational initiatives in thrombolytic therapy. Front Med 2017; 11 (1): 1–19. 46. Kleiser B, Diepers M, Geiger S et al. Combined therapy with f lunarizine and memantine of experimental intracerebral hematoma in rats. Neurol Psych 1995; 3: 219–24. 47. Krzyzanowska W, Pomierny B, Budziszewska B et al. N-Acetylcysteine and Ceftriaxone as Preconditioning Strategies in Focal Brain Ischemia: Influence on Glutamate Transporters Expression. Neurotox Res 2016; 29 (4): 539–50. 48. Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol 2014; 115: 157–88. 49. Lapchak PA. Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. Brain Res 2006; 1088 (1): 141–7. 50. Lee ST, Chu K, Jung KH et al. Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab 2006; 26 (4): 536–44. 51. Lendraitiene E et al. Balance evaluation techniques and physical therapy in post-stroke patients: A literature review. Neurol Neurochir Pol 2017; 51 (1): 92–100. 52. Li Y, Cao LL, Liu L et al. Serum levels of homocysteine at admission are associated with post-stroke depression in acute ischemic stroke. Neurol Sci 2017. 53. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. Neuro Rx 2004; 1: 101–10. 54. Lo EH, Moskowitz MA, Jacobs TP. Exciting, radical, suicidal: how brain cells die after stroke. Stroke 2005; 36 (2): 189–92. 55. Longuemare MC, Swanson RA. Excitatory amino acid release from astrocytes during energy failure by reversal of sodium-dependent uptake. J Neurosci Res 1995; 40 (3): 379–86. 56. López-Dóriga Bonnardeaux P, Andrino Díaz N. Rev Esp Geriatr Gerontol 2016; 51 (3): 164–9. 57. Lopez-Valdes HE, Clarkson AN, Ao Y et al. Memantine enhances recovery from stroke. Stroke 2014; 45 (7): 2093–100. 58. Лукьянюк Е.В., Малюкова Н.Г., Шкловский В.М., Саядян Х.С. Опыт применения акатинола мемантина в резидуальном периоде инсульта. Журн. неврологии и психиатрии им. С.С.Корсакова. Инсульт. Прил. к журн. 2010; 110 (12): 28–33. / Luk'ianiuk E.V., Maliukova N.G., Shklovskii V.M., Saiadian Kh.S. Opyt primeneniia akatinola memantina v rezidual'nom periode insul'ta. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. Insul't. Pril. k zhurn. 2010; 110 (12): 28–33. [in Russian] 59. Mackay J, Mensah GA. The atlas of heart disease and stroke. Geneva: World Health Organization, 2004. 60. Martinez-Badía J, Martinez-Raga J. Who says this is a modern disorder? The early history of attention deficit hyperactivity disorder. World J Psychiatry 2015; 5 (4): 379–86. 61. Mitani A, Imon H, Iga K et al. Gerbil hippocampal extracellular glutamate and neuronal activity after transient ischemia. Brain Res Bull 1990; 25 (2): 319–24. 62. Montagne A, Hebert M, Jullienne A et al. Memantine improves safety of thrombolysis for stroke. Stroke 2012; 43 (10): 2774–81. 63. Motawaj M, Burban A, Davenas E, Arrang JM. Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease. J Pharmacol Exp Ther 2011; 336 (2): 479–87. 64. O'Collins VE, Macleod MR, Donnan GA et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467–77. 65. Orgogozo JM, Rigaud AS, Stoffler A et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834–9. 66. Padma VM, Bhatia R, Kuruttukulam G et al. A call for neurologists to take up stroke intervention. Ann Indian Acad Neurol 2016; 19 (4): 429–32. 67. Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 2007; 53: 699–723. 68. Pena ID, Borlongan C, Shen G, Davis W. Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need. J Stroke 2017; 19 (1): 50–60. 69. Петрова Е.А., Поневежская Е.В., Савина М.А., Скворцова В.И. Клинические особенности постинсультной апатии. Журн. неврологии и психиатрии им. С.С.Корсакова. 2012; 112: 15–9. / Petrova E.A., Ponevezhskaia E.V., Savina M.A., Skvortsova V.I. Clinical features of post stroke apathy. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2012; 112: 15–9. [in Russian] 70. Phillis JW, Ren J, O'Regan MH. Transporter reversal as a mechanism of glutamate release from the ischemic rat cerebral cortex: studies with DL-threo-beta-benzyloxyaspartate. Brain Res 2000; 880 (1–2): 224. 71. Rossi DJ, Brady JD, Mohr C. Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci 2007; 10: 1377–86. 72. Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int 2007; 51 (6–7): 333–55. 73. Shih AY, Blinder P, Tsai PS et al. The smallest stroke: occlusion of one penetrating vessel leads to infarction and a cognitive deficit. Nat Neurosci 2013; 16: 55–63. 74. Sinn DI, Lee ST, Chu K et al. Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. Neurosci Lett 2007; 411 (3): 238–42. 75. Starosta M, Redlicka J, Brzezianski M et al. Brain stroke – risk of disability and possibilities of improvment in motor and cognitive functioning. Pol Merkur Lekarski 2016; 41 (241): 39–42. 76. Stieg PE, Sathi S., Alvardo SP et al. Post-stroke neuroprotection by memantine minimally affects behavior and does not block LTP. Soc Neurosci Abs 1993; 19 (619): 9. 77. Stinear CM. Stroke rehabilitation research needs to be different to make a difference. F1000Res 2016; 5. PII: F1000 Faculty Rev-1467. 78. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database of Syst Rev 2009; 1: CD000197. 79. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol 2007; 6: 182–7. 80. Sutherland BA, Minnerup J, Balami JS et al. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 2012; 7: 407–18. 81. Torp R, Lekieffre D, Levy LM et al. Reduced postischemic expression of a glial glutamate transporter, GLT1, in the rat hippocampus. Exp Brain Res 1995; 103 (1): 51–8. 82. Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke 2011; 42: 2351–5. 83. Trotman M, Vermehren P, Gibson CL, Fern R. The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects. J Cereb Blood Flow Metab 2015; 35 (2): 230–9. 84. Trotman M, Vermehren P, Gibson CL, Fern R. The dichotomy of memant ine treatment for ischemic stroke: dose-dependent protective and detrimental effects. J Cereb Blood Flow Metab 2015; 35 (2): 230–9. 85. Uemura T, Watanabe K, Ishibashi M et al. Aggravation of brain infarction through an increase in acrolein production and a decrease in glutathione with aging. Biochem Biophys Res Commun 2016; 473 (2): 630–5. 86. Valles J, Kennedy J, Elashvili M Dohle C. Memantine Treatment for Post-stroke Aphasia: A Case Control Study (P5.173). Neurology 20 (14). 87. Van Harreveld A. Compounds in brain extracts causing spreading depression of cerebral cortical activity and contraction of crustacean muscle. J Neurochem 1959; 3 (4): 300–15. 88. Volbracht C, van Beek J, Zhu C et al. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci 2006; 23 (10): 2611–22. 89. Wang X, Blanchard J, Grundke-Iqbal I, Iqbal K. Memantine attenuates Alzheimer's disease-like pathology and cognitive impairment. PLoS One 2015; 10 (12): e0145441. 90. Wang YC, Sanchez-Mendoza EH, Doeppner TR, Hermann DM. Post-acute delivery of memantine promotes post-ischemic neurological recovery, peri-infarct tissue remodeling, and contralesional brain plasticity. J Cereb Blood Flow Metab 2016. PII: 0271678X16648971 91. Watanabe T, Iwasaki K, Takasaki K et al. Dynamin 1 depletion and memory deficits in rats treated with Abeta and cerebral ischemia. J Neurosci Res 2010; 88: 1908–17. 92. Yeh TH, Hwang HM, Chen JJ et al. Glutamate transporter function of rat hippocampal astrocytes is impaired following the global ischemia. Neurobiol Dis 2005; 18 (3): 476–83.